IP Library Granted Patent US 8,030,423
Granted Patent B2
US 8,030,423 · App. 12/352,616 · Granted Oct 4, 2011

Multi-armed macromonomers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,030,423
App. No.
12/352,616
Granted
Oct 4, 2011
Kind
B2
Abstract

Multi-armed macromonomers containing multiple side chains attached to a siloxy-containing core terminated on each end with one or more first substantially linear polysiloxane radicals having a polymerizable ethylenically unsaturated-containing terminal group, wherein each side chain comprises a second substantially linear polysiloxane radical having a polymerizable ethylenically unsaturated-containing terminal group are disclosed. Biomedical devices such as contact lenses formed from the multi-armed macromonomers are also disclosed.

Claims (18)

1. A copolymer comprising a polymerization product of a monomeric mixture comprising one or more of multi-armed macromonomers comprising multiple side chains attached to a siloxy-containing core terminated on each end with one or more first substantially linear polysiloxane radicals having a polymerizable ethylenically unsaturated-containing terminal group, wherein each side chain comprises a second substantially linear polysiloxane radical having a polymerizable ethylenically unsaturated-containing terminal group.

2. The copolymer of claim 1 , wherein the polymerizable groups of the first and second substantially linear polysiloxane radicals comprises a vinyl, allyl, vinyloxy, vinyl carbonate, vinyl carbamate, acryloyl, acryloyloxy, methacryloyl, methacryloyloxy, fumaryl, styryl, itaconyl, maleimido, methacrylamido or acrylamido-containing group.

3. The copolymer of claim 1 , wherein the multi-armed macromonomer is of Formula I:

wherein m is at least 1 and each T 1 is independently

wherein y is at least 1, R is independently a monovalent hydrocarbon radical having 1 to 30 carbon atoms which may include ether linkages therebetween, a halogen substituted monovalent hydrocarbon radical having 1 to about 20 carbon atoms which may include ether linkages therebetween, a C 1 -C 20 ester group, an ether or polyether-containing group, an alkyl- or arylamide group, an alkyl- or arylamine group, a substituted or unsubstituted C 1 -C 30 alkoxy group and combinations thereof, X is —O—, and A is independently a polymerizable ethylenically unsaturated-containing radical and T 2 and T 3 are independently hydrogen, a straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a C 1 -C 30 fluoro-substituted alkyl group or alkenyl group, a C 1 -C 20 ester group, an ether or polyether-containing group, an alkyl- or arylamide group, an alkyl- or arylamine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocycloalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, a vinyl group; a C 5 -C 30 fluoroalkyl or fluoroaryl group and combinations thereof and further wherein at least one of T 2 and at least one of T 3 are independently of the same formula as T 1 .

4. The copolymer of claim 1 , wherein the monomeric mixture further comprises a hydrophilic monomer, hydrophobic monomer or both.

5. The copolymer of claim 4 , wherein the hydrophilic monomer is selected from the group consisting of an unsaturated carboxylic acid, (meth)acrylic substituted alcohol, vinyl lactam, (meth)acrylamide and combinations thereof.

6. The copolymer of claim 1 , wherein the monomeric mixture further comprises a hydrophilic monomer selected from the group consisting of 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate, glyceryl methacrylate; N-vinylpyrrolidone; N-vinyl-N-methyl acetamide, N,N-dimethyl methacrylamide, N,N-dimethylacrylamide, acrylic acid, methacrylic acid and combinations thereof.

7. The copolymer of claim 4 , wherein the hydrophobic monomer is a silicone-containing monomer having from 1 to about 20 silicon atoms.

8. The copolymer of claim 4 , wherein the hydrophobic monomer is an aliphatic ring containing monomer selected from the group consisting of isobornyl acrylate, isobornyl methacrylate, cyclohexyl acrylate, cyclohexyl methacrylate and combinations thereof.

9. A biomedical device comprising a polymerization product of a monomeric mixture comprising (a) one or more of multi-armed macromonomers comprising multiple side chains attached to a siloxy-containing core terminated on each end with one or more first substantially linear polysiloxane radicals having a polymerizable ethylenically unsaturated-containing terminal group, wherein each side chain comprises a second substantially linear polysiloxane radical having a polymerizable ethylenically unsaturated-containing terminal group; and (b) a biomedical device-forming comonomer.

10. The biomedical device of claim 9 , wherein the multi-armed macromonomer is of Formula I:

wherein m is at least 1 and each T 1 is independently

wherein y is at least 1, R is independently a monovalent hydrocarbon radical having 1 to 30 carbon atoms which may include ether linkages therebetween, a halogen substituted monovalent hydrocarbon radical having 1 to about 20 carbon atoms which may include ether linkages therebetween, a C 1 -C 20 ester group, an ether or polyether-containing group, an alkyl- or arylamide group, an alkyl- or arylamine group, a substituted or unsubstituted C 1 -C 30 alkoxy group and combinations thereof, X is —O—, and A is independently a polymerizable ethylenically unsaturated-containing radical and T 2 and T 3 are independently hydrogen, a straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 5 -C 30 aryl group, a substituted or unsubstituted C 5 -C 30 arylalkyl group, a C 1 -C 30 fluoro-substituted alkyl group or alkenyl group, a C 1 -C 20 ester group, an ether or polyether-containing group, an alkyl- or arylamide group, an alkyl- or arylamine group, a substituted or unsubstituted C 1 -C 30 alkoxy group, a substituted or unsubstituted C 5 -C 30 heteroaryl group, a substituted or unsubstituted C 3 -C 30 heterocyclic ring, a substituted or unsubstituted C 4 -C 30 heterocycloalkyl group, a substituted or unsubstituted C 6 -C 30 heteroarylalkyl group, a vinyl group; a C 5 -C 30 fluoroalkyl or fluoroaryl group and combinations thereof and further wherein at least one of T 2 and at least one of T 3 are independently of the same formula as T 1 .

11. The biomedical device of claim 9 , wherein the biomedical device-forming comonomer is a silicone-containing monomer.

12. The biomedical device of claim 9 , wherein the monomeric mixture further comprises a hydrophilic monomer, hydrophobic monomer or both.

13. The biomedical device of claim 9 , wherein the biomedical device-forming comonomer is a hydrophilic monomer or hydrophobic monomer.

14. The biomedical device of claim 9 , which is an ophthalmic lens.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Oct 28, 2011
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Reel/Frame 027143/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2009
From: SALAMONE, JOSEPH C.; KUNZLER, JAY F.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 022159/0029 →